Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection
Journal of Antimicrobial Chemotherapy · 02.04.2024 · 79 (4) · 875-882
DOI: 10.1093/jac/dkae046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 23.02.2024. Verfasst von Nicole Cotroneo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Mycobacterium Infections, Nontuberculous, Lung Diseases, Pneumonia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Spero Therapeutics, Inc.
Abstract (Originalsprache)
Background
Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is increasing worldwide, with Mycobacterium avium complex (MAC) and Mycobacterium abscessus as the predominant pathogens. Current treatments are poorly tolerated and modestly effective, highlighting the need for new treatments. SPR719, the active moiety of the benzimidazole prodrug SPR720, inhibits the ATPase subunits of DNA gyrase B, a target not exploited by current antibiotics, and therefore, no cross-resistance is expected with standard-of-care (SOC) agents.
Objectives
To evaluate the in vitro activity of SPR719 against MAC and M. abscessus clinical isolates, including those resistant to SOC agents, and in vivo efficacy of SPR720 in murine non-tuberculous mycobacteria (NTM) pulmonary infection models.
Methods
NTM isolates were tested for susceptibility to SPR719. Chronic C3HeB/FeJ and severe combined immunodeficient murine models of pulmonary infection were used to assess efficacy of SPR720 against MAC and M. abscessus, respectively.
Results
SPR719 was active against MAC (MIC90, 2 mg/L) and M. abscessus (MIC90, 4 mg/L) clinical isolates. Efficacy of SPR720 was demonstrated against MAC pulmonary infection, both as a monotherapy and in combination with SOC agents. SPR720 monotherapy exhibited dose-dependent reduction in bacterial burden, with the largest reduction observed when combined with clarithromycin and ethambutol. Efficacy of SPR720 was also demonstrated against M. abscessus pulmonary infection where monotherapy exhibited a dose-dependent reduction in bacterial burden with further reductions detected when combined with SOC agents.
Conclusions
In vitro activity of SPR720 against common NTM pathogens and efficacy in murine infections warrant the continued clinical evaluation of SPR720 as a new oral option for the treatment of NTM-PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA.
ORCID-Profile: Kamal A Hamed, Ian A Critchley
Förderung
- Spero Therapeutics, Inc
Zitieren
APA
Cotroneo, N., Stokes, S. S., Pucci, M. J., Rubio, A., Hamed, K. A., & Critchley, I. A. (2024). Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection. Journal of Antimicrobial Chemotherapy, 79(4), 875-882. https://doi.org/10.1093/jac/dkae046
Vancouver
Cotroneo N, Stokes SS, Pucci MJ, Rubio A, Hamed KA, Critchley IA. Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection. Journal of Antimicrobial Chemotherapy. 2024;79(4):875-882. doi:10.1093/jac/dkae046
BibTeX
@article{Cotroneo2024,
author = {Cotroneo, Nicole and Stokes, Suzanne S and Pucci, Michael J and Rubio, Aileen and Hamed, Kamal A and Critchley, Ian A},
title = {Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {4},
pages = {875--882},
doi = {10.1093/jac/dkae046}
}
EUVIMED